effect of Sovodak in patients with hepatitis C and HIV-1

A clinical trial to investigate effectiveness of Sovodak on viral load in patients with concurrent hepatitis C and HIV-1

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180924041107N1

Enrollment

Registered

2018-11-19

Start date

2018-08-11

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Hepatitis C and HIV. Condition 2: Human immunodeficiency virus. Acute hepatitis C Human immunodeficiency virus [HIV] disease

Interventions

Intervention group: SOVODAK treatment for three months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients infected with HIV virus who get anti retroviral treatments and simultaneously infected with hepatitis C virus.

Exclusion criteria

Exclusion criteria: patients who previously received treatments for hepatitis C patients with kidney disease patients with advanced cirrhosis

Design outcomes

Primary

Measure	Time frame
Viral load. Timepoint: before treatments and 3 months after treatments. Method of measurement: RTPCR.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRoya Sedghi

Tabriz University of Medical Sciences

r.sedghi111@gmail.com+98 41 3335 1688

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026